RVTY
RevvityCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The quarter beat on revenue and adjusted EPS, diagnostics growth stayed solid, and the China divestiture could improve portfolio quality and mix. The available sell-side target set still sits above the stock, so there is room for a rerate if execution holds.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Adjusted operating margin fell to 23.6% in Q1 from 25.6% a year ago, so operating leverage is not yet fully recovered [#8-K-2026-05-05].
Momentum
53
Value
63
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $111.00 · Bull $126.00 · Bear $86.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $116.79
Why
Momentum53 · Δ7d -2.9
Value63 · Δ7d +0.2
Sentiment45 · Δ7d -1.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
53
26% active weight
Current posture
7d trendFlat
Δ7d
-2.9
Δ21d
-27.1
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.2
Sentiment
45
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.5
Δ21d
+0.7
Why this grade
Composite grade C. Momentum 52.7 / Value 63.0 / Sentiment 44.7
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$11.87B
Beta
1.06
Shares Out
111.56M
P/E (TTM)
52.3
P/S (TTM)
4.11
P/FCF (TTM)
24.94
Rev YoY
+7.0%
EPS YoY
+5.6%
Gross Margin
+47.6%
Op Margin
+12.9%
Net Debt
$2.48B
Current Ratio
1.72
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology